AU2018265257B2 - Atropine pharmaceutical compositions - Google Patents

Atropine pharmaceutical compositions Download PDF

Info

Publication number
AU2018265257B2
AU2018265257B2 AU2018265257A AU2018265257A AU2018265257B2 AU 2018265257 B2 AU2018265257 B2 AU 2018265257B2 AU 2018265257 A AU2018265257 A AU 2018265257A AU 2018265257 A AU2018265257 A AU 2018265257A AU 2018265257 B2 AU2018265257 B2 AU 2018265257B2
Authority
AU
Australia
Prior art keywords
atropine
composition
ophthalmic
low
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018265257A
Other languages
English (en)
Other versions
AU2018265257A1 (en
Inventor
Prem Sagar AKASAPU
Iouri V. ILITCHEV
Irfan A. MOHAMMED
Navneet Puri
Kumaresh Soppimath
Tao Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vyluma Inc
Original Assignee
Vyluma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64096170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018265257(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vyluma Inc filed Critical Vyluma Inc
Publication of AU2018265257A1 publication Critical patent/AU2018265257A1/en
Application granted granted Critical
Publication of AU2018265257B2 publication Critical patent/AU2018265257B2/en
Assigned to VYLUMA INC. reassignment VYLUMA INC. Request for Assignment Assignors: NEVAKAR INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2018265257A 2017-05-11 2018-05-10 Atropine pharmaceutical compositions Active AU2018265257B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505027P 2017-05-11 2017-05-11
US62/505,027 2017-05-11
PCT/US2018/032017 WO2018209051A1 (en) 2017-05-11 2018-05-10 Atropine pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU2018265257A1 AU2018265257A1 (en) 2019-11-14
AU2018265257B2 true AU2018265257B2 (en) 2020-08-06

Family

ID=64096170

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018265257A Active AU2018265257B2 (en) 2017-05-11 2018-05-10 Atropine pharmaceutical compositions

Country Status (23)

Country Link
US (14) US10251875B2 (enExample)
EP (2) EP3548000B1 (enExample)
JP (5) JP6557379B2 (enExample)
KR (1) KR102281667B1 (enExample)
CN (1) CN110621298B (enExample)
AU (1) AU2018265257B2 (enExample)
CA (1) CA3063228C (enExample)
CL (1) CL2019003228A1 (enExample)
CO (1) CO2019012893A2 (enExample)
CY (1) CY1124880T1 (enExample)
ES (1) ES2901140T3 (enExample)
HR (1) HRP20212019T1 (enExample)
HU (1) HUE056595T2 (enExample)
LT (1) LT3548000T (enExample)
MX (1) MX392558B (enExample)
PH (1) PH12019502701A1 (enExample)
PL (1) PL3548000T3 (enExample)
PT (1) PT3548000T (enExample)
RS (1) RS62817B1 (enExample)
RU (1) RU2745603C1 (enExample)
SG (1) SG11201910085UA (enExample)
SI (1) SI3548000T1 (enExample)
WO (1) WO2018209051A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
SG11201809822SA (en) * 2016-05-25 2018-12-28 Singapore Health Serv Pte Ltd Atropine-containing aqueous composition
MX392558B (es) 2017-05-11 2025-03-24 Vyluma Inc Composición oftálmica líquida estable, que comprende una solución acuosa con un tampón, un agente de tonicidad, un quelante, un modificador de la viscosidad y atropina; y el uso de la misma para el tratamiento de la miopía.
CN115300226A (zh) 2017-06-10 2022-11-08 艾诺维亚股份有限公司 用于将一体积的流体输送到眼睛的设备
US11554115B2 (en) * 2018-03-14 2023-01-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative for treatment of triple-negative breast cancer
WO2019216395A1 (ja) * 2018-05-11 2019-11-14 千寿製薬株式会社 眼科用組成物
CN110934816B (zh) * 2018-09-25 2022-04-08 沈阳兴齐眼科医院有限公司 一种提高低浓度阿托品眼用制剂稳定性的方法
WO2020219707A1 (en) * 2019-04-24 2020-10-29 Allergan, Inc. Compositions and methods for treatment of ocular conditions
WO2021001806A1 (en) * 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities
CN115038414A (zh) 2019-12-11 2022-09-09 艾诺维亚股份有限公司 用于向眼睛输送流体的系统和装置及使用方法
JP2023505841A (ja) * 2019-12-16 2023-02-13 シドネキシス，インク． Ｄ２ｏを含む眼科用組成物
CN110917133A (zh) * 2019-12-23 2020-03-27 河北科技大学 一种治疗近视的滴眼剂及其制备方法
WO2021226153A1 (en) * 2020-05-05 2021-11-11 The Procter & Gamble Company Oral care compositions comprising dicarboxylic acid
CN111821259A (zh) * 2020-07-14 2020-10-27 艾尔健康眼药(辽宁)有限公司 一种眼用药物组合物
CN111840221A (zh) * 2020-08-25 2020-10-30 安徽博诺美科生物医药有限公司 一种硫酸阿托品滴眼液
WO2022130033A1 (en) * 2020-12-17 2022-06-23 Sun Pharmaceutical Industries Limited An aqueous sterile solution of atropine for ophthalmic use
EP4308080A4 (en) * 2021-03-16 2025-02-26 Vyluma Inc. MULTI-DOSE CONTAINERS FOR OPHTHALMIC COMPOSITIONS
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
CN113440486B (zh) * 2021-06-02 2022-12-20 苏州欧康维视生物科技有限公司 一种用于预防或治疗眼科疾病的滴眼剂组合物及其制备方法
CN117295491A (zh) * 2021-09-13 2023-12-26 安徽欧普视方医药科技有限公司 阿托品滴眼液及其制备方法
CN118541148A (zh) 2021-11-10 2024-08-23 视觉治疗股份有限公司 增强抗老花眼作用的碳酰胆碱制剂
CN114129511A (zh) * 2021-12-07 2022-03-04 河南润弘制药股份有限公司 一种具有改进稳定性的硫酸阿托品注射液
WO2023152642A1 (en) * 2022-02-08 2023-08-17 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
CN114569551A (zh) * 2022-03-21 2022-06-03 杭州赫尔斯科技有限公司 阿托品滴眼液及其制备方法
WO2023201315A2 (en) * 2022-04-14 2023-10-19 TearClear Corp. Ophthalmic agent in preservative removal device
CN115177584A (zh) * 2022-07-14 2022-10-14 成都市海通药业有限公司 一种硫酸阿托品注射液的制备方法
WO2024091789A1 (en) * 2022-10-26 2024-05-02 Vyluma Inc. Childhood atropine for myopia progression
CN115998692A (zh) * 2023-02-15 2023-04-25 苏州欧康维视生物科技有限公司 一种阿托品药物产品及其用途
WO2025146828A1 (ja) * 2024-01-05 2025-07-10 ロート製薬株式会社 眼科組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160009705A1 (en) * 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86521A1 (fr) 1986-07-18 1988-02-02 Oreal Procede de teinture des cheveux avec des colorants hydroxyquinoniques et des sels metalliques
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (ja) 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
SE9401108D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US20030129083A1 (en) 1997-11-26 2003-07-10 Advanced Medical Optics, Inc. Multi purpose contact lens care compositions including propylene glycol or glycerin
US6164282A (en) 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia
EP1301210A2 (en) * 2000-07-14 2003-04-16 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
CN101049287A (zh) 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
BRPI0819081A8 (pt) * 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
WO2010083129A2 (en) 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
EP2464387A4 (en) 2009-08-12 2013-05-15 Seros Medical Llc DEUTERATED WATER SOLUTION AND RIBOFLAVIN FOR EXTENDED OXYGEN SINGULET LIFETIME IN THE TREATMENT OF OCULAR TISSUE AND METHOD OF USE
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
WO2014119642A1 (ja) * 2013-01-31 2014-08-07 千寿製薬株式会社 安定な水性液剤
KR102027663B1 (ko) 2013-05-06 2019-10-01 가오슝 창 궁 메모리얼 하스피털 약학적 조성물 및 이의 용도
EP3973954A1 (en) * 2013-10-15 2022-03-30 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
WO2016013993A1 (en) 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
WO2016187426A1 (en) 2015-05-19 2016-11-24 Amorphex Therapeutics Llc A device that delivers a sustained low-dose of a myopia-suppressing drug
CN107920984A (zh) * 2015-06-18 2018-04-17 远视眼治疗有限责任公司 储存稳定的组合物以及治疗眼睛屈光不正的方法
SG11201809822SA (en) 2016-05-25 2018-12-28 Singapore Health Serv Pte Ltd Atropine-containing aqueous composition
MX392558B (es) 2017-05-11 2025-03-24 Vyluma Inc Composición oftálmica líquida estable, que comprende una solución acuosa con un tampón, un agente de tonicidad, un quelante, un modificador de la viscosidad y atropina; y el uso de la misma para el tratamiento de la miopía.
US11191751B1 (en) 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160009705A1 (en) * 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition

Also Published As

Publication number Publication date
MX392558B (es) 2025-03-24
HUE056595T2 (hu) 2022-02-28
JP2019172704A (ja) 2019-10-10
SI3548000T1 (sl) 2022-02-28
SG11201910085UA (en) 2019-11-28
HRP20212019T1 (hr) 2022-04-01
US20210128546A1 (en) 2021-05-06
EP3548000B1 (en) 2021-11-10
CN110621298A (zh) 2019-12-27
CL2019003228A1 (es) 2020-01-31
CO2019012893A2 (es) 2020-02-28
US20190183876A1 (en) 2019-06-20
US11730728B2 (en) 2023-08-22
US20200352928A1 (en) 2020-11-12
PT3548000T (pt) 2021-12-10
US20230355604A1 (en) 2023-11-09
US11071732B2 (en) 2021-07-27
US10610525B2 (en) 2020-04-07
ES2901140T3 (es) 2022-03-21
EP3548000A4 (en) 2019-12-04
RU2745603C1 (ru) 2021-03-29
KR20190138714A (ko) 2019-12-13
JP7332179B2 (ja) 2023-08-23
US10251875B2 (en) 2019-04-09
AU2018265257A1 (en) 2019-11-14
US20240342154A1 (en) 2024-10-17
US10568875B2 (en) 2020-02-25
CY1124880T1 (el) 2022-11-25
US20190175580A1 (en) 2019-06-13
MX2019013218A (es) 2022-05-24
US20200405705A1 (en) 2020-12-31
PH12019502701A1 (en) 2020-12-07
US20190192499A1 (en) 2019-06-27
JP6681502B2 (ja) 2020-04-15
US12036217B2 (en) 2024-07-16
CN110621298B (zh) 2022-12-20
EP3548000A1 (en) 2019-10-09
JP2019194248A (ja) 2019-11-07
US11464769B2 (en) 2022-10-11
EP3970694A1 (en) 2022-03-23
JP2018188440A (ja) 2018-11-29
JP2021102647A (ja) 2021-07-15
US20200397775A1 (en) 2020-12-24
WO2018209051A1 (en) 2018-11-15
US11707458B2 (en) 2023-07-25
PL3548000T3 (pl) 2022-01-17
KR102281667B1 (ko) 2021-07-23
US11730727B2 (en) 2023-08-22
US10576074B2 (en) 2020-03-03
US11642338B2 (en) 2023-05-09
US20200397776A1 (en) 2020-12-24
JP2019172705A (ja) 2019-10-10
JP6865476B2 (ja) 2021-04-28
JP6681503B2 (ja) 2020-04-15
NZ758555A (en) 2021-10-29
US20180325888A1 (en) 2018-11-15
US10583132B2 (en) 2020-03-10
KR102281667B9 (ko) 2024-01-08
CA3063228C (en) 2022-06-28
LT3548000T (lt) 2022-03-10
CA3063228A1 (en) 2018-11-15
US20190209545A1 (en) 2019-07-11
BR112019023515A2 (pt) 2020-05-19
USRE50040E1 (en) 2024-07-16
JP6557379B2 (ja) 2019-08-07
US20190175579A1 (en) 2019-06-13
RS62817B1 (sr) 2022-02-28

Similar Documents

Publication Publication Date Title
US12036217B2 (en) Atropine pharmaceutical compositions
HK40069136A (en) Atropine pharmaceutical compositions
HK40016019A (en) Atropine pharmaceutical compositions
HK40016019B (en) Atropine pharmaceutical compositions
NZ758853A (en) Adhesive comprising finely pulverized bark
NZ758853B2 (en) Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: VYLUMA INC.

Free format text: FORMER OWNER(S): NEVAKAR INC.